While the immune response to ICI therapies differs in HCC compared to many other cancers, granzyme B may still be a potential biomarker for immunotherapy efficacy in liver cancer providing useful information to help improve patient management. The gene discussed is GZMB; the disease is hepatocellular carcinoma.